Evidence map›Paper›PMID 38293184›Full record

ArticlebioRxiv : the preprint server for biology2024

miRNA family miR-29 inhibits PINK1-PRKN dependent mitophagy via ATG9A.

Briana N Markham, Chloe Ramnarine, Songeun Kim, William E Grever, Alexandra I Soto-Beasley, Michael Heckman, Yingxue Ren, Andrew C Osborne, Aditya V Bhagwate, Yuanhang Liu and 6 more

Open access · greenAbstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 6 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 1 country.

Briana N MarkhamDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.
Chloe RamnarineDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.
Songeun KimDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.
William E GreverRevvity, Waltham, MA 02451, USA.
Alexandra I Soto-BeasleyDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.
Michael HeckmanDivision of Clinical Trials and Biostatistics, Mayo Clinic, Jacksonville, FL 32224, USA.
Yingxue RenDepartment of Quantitative Health Science, Mayo Clinic, Jacksonville, FL 32224, USA.
Andrew C OsborneDepartment of Quantitative Health Science, Mayo Clinic, Rochester, MN 55905, USA.
Aditya V BhagwateDepartment of Quantitative Health Science, Mayo Clinic, Rochester, MN 55905, USA.
Yuanhang LiuDepartment of Quantitative Health Science, Mayo Clinic, Rochester, MN 55905, USA.
Chen WangDepartment of Quantitative Health Science, Mayo Clinic, Rochester, MN 55905, USA.
Jungsu KimDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.
Zbigniew K WszolekDepartment of Neurology, Mayo Clinic, Jacksonville, FL 32224, USA.
Owen A RossDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.
Wolfdieter SpringerDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.ORCID 0000-0002-1178-3149
Fabienne C FieselDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.ORCID 0000-0002-1919-9676
Mayo Clinic in Florida · USBVI (United States) · USJacksonville College · US

Funding

Technology and Remote Assessment CoreU19AG063911 · NIA · MAYO CLINIC ROCHESTER · PI ADAM L. BOXER · 2019 to 2026
$120.9M
Utilization of proteomics and lipidomics to identify modifiers of LBDU54NS110435 · NINDS · MAYO CLINIC JACKSONVILLE · PI MCLEAN, PAMELA J · 2019 to 2023
$14.5M
Molecular mechanisms of PINK1-PRKN directed mitochondrial quality controlRF1NS085070 · NINDS · MAYO CLINIC JACKSONVILLE · PI SPRINGER, WOLFDIETER · 2019 to 2019
$2.8M
Mitochondrial Sirtuin 3 in Parkinson's diseaseR01NS110085 · NINDS · MAYO CLINIC JACKSONVILLE · PI MCLEAN, PAMELA J, SPRINGER, WOLFDIETER · 2019 to 2023
$2.5M
Selective autophagy in Alzheimer's disease and related dementiasR56AG062556 · NIA · MAYO CLINIC JACKSONVILLE · PI FRYER, JOHN DAVID, SPRINGER, WOLFDIETER · 2019 to 2019
$782k
NIA NIH HHS R56 AG062556NIA NIH HHS U19 AG063911NINDS NIH HHS R01 NS110085NINDS NIH HHS RF1 NS085070NINDS NIH HHS U54 NS110435
6 · The paper itself

Abstract

Loss-of-function mutations in the genes encoding PINK1 and PRKN result in early-onset Parkinson disease (EOPD). Together the encoded enzymes direct a neuroprotective pathway that ensures the elimination of damaged mitochondria via autophagy. We performed a genome-wide high content imaging miRNA screen for inhibitors of the PINK1-PRKN pathway and identified all three members of the miRNA family 29 (miR-29). Using RNAseq we identified target genes and found that siRNA against ATG9A phenocopied the effects of miR-29 and inhibited the initiation of PINK1-PRKN mitophagy. Furthermore, we discovered two rare, potentially deleterious, missense variants (p.R631W and p.S828L) in our EOPD cohort and tested them experimentally in cells. While expression of wild-type ATG9A was able to rescue the effects of miR-29a, the EOPD-associated variants behaved like loss-of-function mutations. Together, our study validates miR-29 and its target gene ATG9A as novel regulators of mitophagy initiation. It further serves as proof-of-concept of finding novel, potentially disease-causing EOPD-linked variants specifically in mitophagy regulating genes. The nomination of genetic variants and biological pathways is important for the stratification and treatment of patients that suffer from devastating diseases, such as EOPD.

Indexed as

ATG9Ahsa-miR-29mitophagyParkinParkinson’s diseasePINK1PRKN

Identifiers

PMID38293184
PMCPMC10827147
OpenAlexW4391044929

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.